In short
Clinical trials investigating Interferon Alfa are studying whether it helps in infections linked to warts, human papillomavirus (HPV), and Epstein-Barr virus (EBV). These trials mainly evaluate efficacy, such as symptom or infection clearance, in patients with non-genital warts, genital HR-HPV infection, and EBV-related fatigue.
Key points
- Clinical trials investigating Interferon Alfa are focused on infections and related symptoms, not on a general drug monograph. The available studies include non-genital warts infection, high-risk HPV genital infection, and Epstein-Barr virus infection. Two trials are Phase 3 studies, and one is listed as Low Intervention. All three trials are authorised and compare a study treatment with placebo. The main outcomes are wart disappearance, HPV clearance, and fatigue improvement. These trials involve patients with the specific infection being studied.
Trial overview
The trial data provided here includes three interventional studies, which means the researchers are giving a treatment and then measuring the results. All three studies are authorised and compare a study treatment with placebo, which is a look-alike treatment without the active study drug.
The studies target different conditions: non-genital warts infection, human papillomavirus infection, and Epstein-Barr virus infection. The main question in these trials is whether the study treatment works better than placebo for the chosen outcome, such as clearing infection or improving symptoms.
Study in non-genital warts
The trial NCT03977753 is a randomized, placebo-controlled, double-blind study in people with non-genital warts infection. Randomized means participants are assigned by chance, and double-blind means neither the participants nor the researchers know who gets which treatment during the study.
This study compares 2LVERU® JUNIOR and 2LVERU® with placebo, and it is listed as Low Intervention with 162 planned participants. The main endpoint is the disappearance of warts at the end of treatment, measured at the 6-month visit.
Study in high-risk HPV infection
The trial NCT04232917 is a randomized, placebo-controlled, double-blind Phase 3 study in people with human papillomavirus infection, specifically high-risk oncogenic genital HPV infection. Phase 3 means the study is a later-stage trial that usually includes more participants and checks how well a treatment works compared with a control group.
This study compares 2LPAPI® with placebo and has 484 planned participants. The primary outcome is HR-HPV infection clearance at the 12-month visit, which means the researchers want to see whether the infection is gone by that time.
Study in EBV infection
The trial NCT04308278 is a randomized, placebo-controlled, double-blind Phase 3 study in people with Epstein-Barr virus infection. It compares 2LEBV® and 2LXFS® with placebo and includes 88 planned participants.
The main outcome is the general fatigue scale of the MFI-20 questionnaire at the end of treatment, measured at the 6-month visit. This means the study is focused on whether the treatment improves tiredness, which is a common symptom measured with a patient questionnaire.
Common study design and endpoints
Across these trials, the researchers are using placebo comparison to help show whether the study treatment has an effect beyond no active treatment. This is important because it gives a clearer picture of the treatment result in each condition.
The main endpoints are different because each trial measures the outcome that matters most for that condition: wart disappearance, HPV clearance, or fatigue improvement. A primary outcome is the main result the study is designed to measure.
What these trials may mean for patients
These studies are for people who have the specific infection or symptom being tested in each trial, such as warts, HPV infection, or EBV infection. The trial data does not give full eligibility rules, so the exact who-can-join details are not shown here.
For patients, the key point is that these studies are testing whether the study treatment can help with visible warts, viral infection clearance, or fatigue symptoms. The results will depend on the trial endpoint and the group being studied.